National trends in prostate cancer screening among older American men with limited 9-year life expectancies: Evidence of an increased need for shared decision making

Cancer

Volumn 120, Issue 10, 2014, Pages 1491-1498

  Drazer, Michael W ^a   Prasad, Sandip M ^b   Huo, Dezheng ^a   Schonberg, Mara A ^c   Dale, William ^a   Szmulewitz, Russell Z ^a   Eggener, Scott E ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

guidelines; life expectancy; mortality; prostate cancer screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CAUCASIAN; COHORT ANALYSIS; DECISION MAKING; EARLY DIAGNOSIS; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT PREFERENCE; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL PREDICTION; TREND STUDY; UNITED STATES;

GUIDELINES; LIFE EXPECTANCY; MORTALITY; PROSTATE CANCER SCREENING;

ACTIVITIES OF DAILY LIVING; AGE FACTORS; AGED; AGED, 80 AND OVER; BODY MASS INDEX; COMORBIDITY; CROSS-SECTIONAL STUDIES; DECISION MAKING; EARLY DETECTION OF CANCER; HEALTH STATUS; HUMANS; LIFE EXPECTANCY; LOGISTIC MODELS; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SMOKING; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84899904962     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28600     Document Type: Article

References (23)

1. Moyer VA, US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157: 120-134.
2. US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149: 185-191.
3. Smith RA, Brooks D, Cokkinides V, Saslow D, Brawley OW,. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin. 2013; 63: 88-105.
4. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013; 190: 419-426.
5. Kawachi MH, Bahnson RR, Barry M, et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw. 2010; 8: 240-262.
6. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360: 1310-1319.
7. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 1320-1328.
8. Grenabo Bergdahl A, Holmberg E, Moss S, Hugosson J,. Incidence of prostate cancer after termination of screening in a population-based randomised screening trial. Eur Urol. 2013; 64: 703-709.
9. Johansson E, Bill-Axelson A, Holmberg L, et al. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol. 2009; 55: 422-430.
10. Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA. 2011; 306: 1205-1214.
11. Bechis SK, Carroll PR, Cooperberg MR,. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol. 2011; 29: 235-241.
12. Schonberg MA, Davis RB, McCarthy EP, Marcantonio ER,. External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older. J Am Geriatr Soc. 2011; 59: 1444-1451.
13. Centers for Disease Control and Prevention. About the National Health Interview Survey. Available at: http://www.cdc.gov/nchs/nhis/about-nhis.htm. Accessed June 11, 2013.
14. Anderson RN,. A method for constructing complete annual US life tables. Vital Health Stat 2. 2000; 129: 1-28.
15. Kotwal AA, Mohile SG, Dale W,. Remaining life expectancy measurement and PSA screening of older men. J Geriatr Oncol. 2012; 3: 196-204.
16. Drazer MW, Huo D, Schonberg MA, Razmaria A, Eggener SE,. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol. 2011; 29: 1736-1743.
17. Walter LC, Bertenthal D, Lindquist K, Konety BR,. PSA screening among elderly men with limited life expectancies. JAMA. 2006; 296: 2336-2342.
18. Prasad SM, Drazer MW, Huo D, Hu JC, Eggener SE,. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA. 2012; 307: 1692-1694.
19. Davis K, Haisfield L, Dorfman C, Krist A, Taylor KL,. Physicians' attitudes about shared decision making for prostate cancer screening. Fam Med. 2011; 43: 260-266.
20. Pollack CE, Platz EA, Bhavsar NA, et al. Primary care providers' perspectives on discontinuing prostate cancer screening. Cancer. 2012; 118: 5518-5524.
21. Lewis CL, Kistler CE, Amick HR, et al. Older adults' attitudes about continuing cancer screening later in life: a pilot study interviewing residents of 2 continuing care communities [serial online]. BMC Geriatr. 2006; 6: 10.
22. Jeldres C, Latouff JB, Saad F,. Predicting life expectancy in prostate cancer patients. Curr Opin Support Palliat Care. 2009; 3: 166-169.
23. Hall HI, Van Den Eeden SK, Tolsma DD, et al. Testing for prostate and colorectal cancer: comparison of self-report and medical record audit. Prev Med. 2004; 39: 27-35.